Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes

Laura Feeney, Ian JG Harley, W Glenn McCluggage, Paul B Mullan, James P Beirne*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

50 Downloads (Pure)

Abstract

Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy in the western world. The majority of women presenting with the disease are asymptomatic and it has been dubbed the "silent killer". To date there is no effective minimally invasive method of stratifying those with the disease or screening for the disease in the general population. Recent molecular and pathological discoveries, along with the advancement of scientific technology, means there is a real possibility of having disease-specific liquid biopsies available within the clinical environment in the near future. In this review we discuss these discoveries, particularly in relation to the most common and aggressive form of EOC, and their role in making this possibility a reality.

Original languageEnglish
Pages (from-to)868-889
Number of pages22
JournalWorld Journal of Clinical Oncology
Volume11
Issue number11
DOIs
Publication statusPublished - 24 Nov 2020

Bibliographical note

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Fingerprint

Dive into the research topics of 'Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes'. Together they form a unique fingerprint.

Cite this